What we do Auro Laboratories Ltd manufactures generic Active Pharmaceutical Ingredients, primarily Anti-Diabetic drugs like Metformin HCL, focusing on quality and international export markets. |
Founded in 1,992 |
Market share Leading manufacturer of Metformin HCL with growing international presence in Europe, Middle East, and South East Asia markets. |
Problem solved Provides essential and affordable generic Anti-Diabetic APIs addressing global diabetes treatment demands. |
Top clients or who we serve Pharmaceutical companies globally, exporting to countries including Germany, Spain, UK, Brazil, Egypt, Malaysia, and Singapore. B2B model. |
Key management Chairman and Managing Director: Mr. Sharat Deorah; Whole-time Director: Mr. Siddhartha Deorah. |
Our journey and innovations Founded in 1992, expanded Metformin HCL capacity from 1800 to 3600 MTPA by 2025; received multiple WHO and European certifications. |
Where we operate Exports to Europe, Middle East, South East Asia, Africa, and South America with domestic manufacturing in India. |
Top products or what we offer Metformin Hydrochloride, Glibenclamide APIs, and contract manufacturing of other pharmaceutical ingredients. |
Top brands Metformin HCL API – key revenue driver; WHO cGMP and EDQM certified product ensuring international quality compliance. |
Raw materials needed Chemical raw materials for API synthesis, sourced from various suppliers (not detailed). |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue is primarily cyclical, linked to pharma demand cycles and contract manufacturing engagements. |
Our industry position Recognized micro-cap API manufacturer with strong foothold in anti-diabetic segment and expanding capacity. |
Financial highlights Revenue Rs.19.4 Crores; Net Profit Rs.1.84 Crores for FY 2024-25 reflecting scale and profitability. |
Geographical revenue split Significant export revenue from Europe, South East Asia, Middle East, and Africa; remainder from domestic sales. |
Order book - |
Whats driving growth Capacity expansion doubling Metformin production, global anti-diabetic drug demand, and regulatory certifications driving exports. |
Our future plans Focus on increasing capacity and diversifying product portfolio within anti-diabetic APIs; consolidating international market presence. |
Our green promise Committed to energy conservation and reducing emissions, aligning with environmental best practices. |
Our people and values Strong employee focus on safety, ethical conduct, and compliance with codes of conduct and anti-harassment policies. |
Key challenges ahead Managing regulatory compliance, global competition, and sustaining growth amid pharmaceutical industry dynamics. |
Interesting facts First Indian company with EDQM Certificate of Suitability for Metformin API and extensive global export footprint. |
Risks and strategy Mitigates market and regulatory risks through diversified exports, quality certifications and capacity expansions. |
